Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) through non-specialist providers and telemedicine: a study protocol for a non-inferiority randomized controlled trial

D. R. Singla1,2*, S. E. Meltzer-Brody3†, R. K. Silver4†, S. N. Vigod2,5, J. J. Kim4,6†, L. M. La Porte4†, P. Ravitz1,2†, C. E. Schiller3†, N. Schoueri-Mychasiw†, S. D. Hollon7, A. Kiss8, D. Clark9, A. K. Dalfen1,2, S. Dimidjian10, B. N. Gaynes3, S. R. Katz2, A. Lawson5†, M. Leszcz1,2, R. G. Maunder1,2, B. H. Mulsant11, J. E. Murphy2,12, J. A. Naslund13, M. L. Reyes-Rodríguez3, A. M. Stuebe14, C-L Dennis2,15,16† and V. Patel14,17†

Abstract

Background: Depression and anxiety impact up to 1 in 5 pregnant and postpartum women worldwide. Yet, as few as 20% of these women are treated with frontline interventions such as evidence-based psychological treatments. Major barriers to uptake are the limited number of specialized mental health treatment providers in most settings, and problems with accessing in-person care, such as childcare or transportation. Task sharing of treatment to non-specialist providers with delivery on telemedicine platforms could address such barriers. However, the equivalence of these strategies to specialist and in-person models remains unproven.

Methods: This study protocol outlines the Scaling Up Maternal Mental healthcare by Increasing access to Treatment (SUMMIT) randomized trial. SUMMIT is a pragmatic, non-inferiority test of the comparable effectiveness of two types of providers (specialist vs. non-specialist) and delivery modes (telemedicine vs. in-person) of a brief, behavioral activation (BA) treatment for perinatal depressive and anxiety symptoms. Specialists (psychologists, psychiatrists, and social workers with ≥ 5 years of therapy experience) and non-specialists (nurses and midwives with no formal training in mental health care) were trained in the BA protocol, with the latter supervised by a BA expert during treatment delivery. Consenting pregnant and postpartum women with Edinburgh Postnatal Depression Scale (EPDS) score of ≥ 10 (N = 1368) will be randomized to one of four arms (telemedicine specialist, (Continued on next page)
Introduction

Background

Depression is a leading cause of disability worldwide [1] with an estimated 10 to 15% of women worldwide experiencing depression during pregnancy or the year following childbirth [2, 3]. Symptoms often begin in the antenatal period [4], and estimates of the annualized lifetime costs of perinatal depression amount to over $45.9 billion USD dollars in the USA alone [5]. Although given less attention than depression, up to 20% of mothers also experience anxiety symptoms [6] and approximately 10% are co-morbid for both [7]. The negative impact of these disorders on mother and child [8–10] underscores the importance of addressing perinatal mental health.

Psychological treatments, such as cognitive, behavioral, and interpersonal therapies, are first-line, effective interventions for perinatal depression and anxiety [11, 12] and are preferred by many women over pharmacotherapy [13, 14]. Despite the recent US Preventive Task Force Recommendations for evidence-based psychological treatments for perinatal populations [15], as few as 20% of affected women are treated with adequate treatments in North America [16]. Barriers include childcare needs, costs, transportation, and stigma [13, 17], in addition to the paucity and inequitable distribution of mental health professionals across settings. Given their prevalence and detrimental impact, developing low-cost, innovative solutions to improve access to psychological treatments for perinatal depression and anxiety is a public health priority. This is particularly true in the context of the COVID-19 pandemic and its impact on mental health symptoms.

Task-sharing is used worldwide to improve access to care, with non-specialist providers (NSPs)—individuals with no formal training in delivering mental health care such as nurses, peers, lay counselors, midwives, teachers, and primary care doctors—trained to effectively treat perinatal depressive and anxiety symptoms [18, 19]. NSPs are widely available, affordable, and often have regular contact with women in the course of their healthcare during pregnancy and the postpartum period [18, 20, 21]. NSPs have effectively delivered behavioral activation (BA) to reduce maternal depressive symptoms [22, 23], anxiety symptoms [23], and intimate partner violence among women of childbearing age [22]. In high-income countries, nurses and midwives are among the most likely to deliver effective psychological interventions [24] and appear to be a preferred type of NSP by perinatal women [25]. Whether specialists and NSPs are equally effective in targeting perinatal depressive and anxiety symptoms when delivering the same treatment remains unknown.

Telemedicine-based psychological treatments offer an alternative approach for perinatal women in terms of flexibility [26], efficiency [27], and cost [28]. This delivery method also increases accessibility and scalability. Recent reviews suggest that telemedicine is as efficacious as in-person psychotherapy on depression and anxiety are similar [29, 30]. However, most of these studies have not compared in-person visits to telemedicine platforms and are underpowered to establish equivalence of the two treatment formats [30].

BA proposes that the key to reducing depression and anxiety is to increase enjoyable or fulfilling activities that align with one’s values [31, 32], targeting key mechanisms of patient activation and avoidant coping. BA has strong evidence for its effectiveness in treating depression in the general population [33, 34]. A randomized placebo controlled study in the USA found that BA was as efficacious as, and more enduring than, antidepressant medication, with fewer patients dropping out of treatment [35, 36]; in the USA and UK, BA was as effective as longer courses of cognitive behavioral therapy [36, 37]. BA was also as effective in treating perinatal

Discussion: The SUMMIT trial is expected to generate evidence on the non-inferiority of BA delivered by a non-specialist provider compared to specialist and telemedicine compared to in-person. If confirmed, results could pave the way to a dramatic increase in access to treatment for perinatal depression and anxiety.

Trial registration: ClinicalTrials.gov NCT 04153864. Registered on November 6, 2019.

Keywords: Depression, Anxiety, Psychological treatments, Behavioral activation, Telemedicine, Perinatal, Randomized controlled trial
Primary objectives
The primary objectives of this study are twofold:

1. To examine if BA can be delivered as effectively by NSPs as specialists in treating perinatal depressive symptoms, as measured by the Edinburgh Postnatal Depression Scale (EPDS) \[44\]; and
2. To examine if BA delivered through telemedicine is as effective as BA delivered through in-person format, in treating perinatal depressive symptoms as measured by the EPDS \[44\].

Secondary objectives
1. To examine the aforementioned questions on anxiety symptoms, as measured by the Generalized Anxiety Disorder-7 (GAD-7) \[45\].
2. To assess moderating effects of clinical severity and treatment timing (antenatal vs. postnatal) on the comparative effectiveness of the two delivery formats on depressive and anxiety symptoms;
3. To determine whether timing of the treatment influences child mental development at 9 to 15 months post childbirth; and
4. To describe the underlying processes, barriers, and facilitators to the delivery of BA for perinatal depressive and anxiety symptoms from a multi-stakeholder perspective.

The COVID-19 pandemic has amplified the need for effective mental healthcare and led to a dramatic increase in the use and role of telemedicine platforms \[46\]. While following key guidelines for preserving clinical trial integrity, the study has continued during the pandemic \[47\]. A list of adaptations made to study implementation is presented in Table 5.

Methods—design, setting, participants, interventions, and outcomes
Trial design
This is a multi-center, four-arm, randomized, non-inferiority trial to test the comparable effectiveness of delivery mode (telemedicine vs. in-person) and provider (NSP vs. SP), implementing a brief, evidence-based BA treatment for perinatal depressive and anxiety symptoms. In this trial, we will also determine the underlying processes related to delivery of this brief psychological intervention from a multi-stakeholder perspective. The protocol conforms to the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) guidelines (see Additional file 1: Figure S1 and Additional file 2: SPIRIT checklist).

Setting
The study takes place in three hubs—Toronto, Chapel Hill, and Chicago. In Toronto, recruitment is at Sinai Health (SH), Women’s College Hospital (WCH), and St. Michael’s Hospital (SMH)—three academic hospitals affiliated with the University of Toronto. In North Carolina, we are recruiting from three clinical sites affiliated with the University of North Carolina (UNC) Women’s and Neuroscience Hospitals. In Chicago, we are recruiting from fourteen affiliated obstetric and family medicine clinics affiliated with NorthShore University HealthSystem and the University of Chicago.

Participants and procedures
We plan to recruit 1368 pregnant and postpartum women aged ≥18 (Fig. 1). Inclusion and exclusion criteria are detailed in Table 1. The study is introduced to eligible women by a trained research assistant or one of the women’s clinical providers at their respective study site. Recruitment and informed consent are acquired in-person or via telephone, using Research Electronic Data Capture system (REDCap™). After consenting to participate, women are screened on the Edinburgh Postnatal Depression Scale (EPDS ≥10 \[44\]) for eligibility. A systematic effort is made to recruit ethnically diverse populations, including women from Latinax communities. For example, bilingual research assistants at the US sites introduce the study in Spanish with a translated consent form. In-person study activities have been paused since the onset of the COVID-19 pandemic (see Table 5).

Treatment and intervention arms
Treatment
The SUMMIT treatment consists of six to eight individual weekly BA sessions. The manual was adapted from two well-established source manuals—the Alma Program for perinatal populations in Colorado and the Healthy Activity Program (HAP \[22, 48\]) from Goa, India. Key strategies include: psychoeducation, behavioral assessment, values-based activity monitoring and structuring, interpersonal effectiveness, and problem solving. Unlike cognitive behavioral interventions for depression, BA explicitly targets avoidant coping \[49\] and has been effective in reducing anxiety symptoms \[50\].
**Intervention arms**
Participants are randomized to one of four arms (Fig. 2):

**Non-specialists vs. specialists**
SUMMIT treatment providers include both NSPs and specialist providers (SPs). NSPs are registered nurses (RNs) or midwives with general health care professional skills but without formal training in mental health care or experience delivering psychotherapies. SPs include individuals with formal training in mental health care delivery (e.g., psychiatrists, psychologists, and social workers) and with experience in treating mental illness and a minimum of 5 years of experience delivering psychological treatments.

**Telemedicine vs. in-person**
Telemedicine is implemented via the Ontario Telemedicine Network and Zoom™ in Toronto, the UNC TelePsychiatry Program in Chapel Hill, and Zoom™ in Chicago. All platforms (1) permit video-visits and scheduling; (2) are accessible on PC, Mac, Android and iOS systems; and (3) are PHIPA/HIPAA compliant. For participants lacking access to a technology, study tablets are provided for use on a temporary basis. Participants assigned to telemedicine can conduct BA sessions in a preferred private location (e.g., home). In-person sessions are held at participating clinical care sites (paused during COVID-19).

**Recruitment, training, supervision of treatment providers**
The same procedures were implemented in each hub.

**Recruitment**
All NSPs were recruited through advertisements in relevant listservs and word of mouth and selected based on

---

**Table 1 Inclusion and exclusion criteria**

| Inclusion | Exclusion |
|-----------|-----------|
| • EPDS ≥ 10 |
| • ≥ 18 years |
| • Pregnant up to 36 weeks or 4 to 30 weeks postpartum |
| • Speaks English or (US sites) Spanish |
| • Active suicidal intent (ideation and plan), active symptoms of psychosis or mania |
| • Psychotropic medication dose or medication change within 2 weeks of enrollment or beginning treatment |
| • Ongoing psychotherapy |
| • Active substance abuse or dependence |
| • Severe fetal anomalies, stillbirth, or infant death at time of enrollment for index pregnancy |
| • Non-English, non-Spanish speakers |
their performance in a structured interview and role-play during an intake interview. A mock patient was incorporated and the Therapy Quality Scale was used to rate the potential provider [51]. SPs were recruited through advertisements and word of mouth. They were selected based on location, interest and availability, and good standing with their respective colleges.

Training and competency tests
Separate workshops were held to train NSPs and SPs. A minimum of two clinical leads conducted each training workshop to ensure consistency across hubs. Clinical leads are expert clinicians and co-Is (PR in Toronto, CS in Chapel Hill, and JJK and LML in Chicago) who are designated to oversee the training and clinical implementation of the BA treatment along with supervision. The workshops utilized observation and didactics with interactive educational strategies including role play, games, and homework. The primary objectives of the training workshops (see Table 2) were to prepare the providers to implement the BA manual and SUMMIT protocol with its safety procedures, including when to refer a participant for post-trial care. Trainees meeting competency standards (based on a multiple-choice questionnaire [52] and in an interaction with a standardized patient (actor) rated by experts using an adapted version of the Quality of HAP (Q-HAP scale) [51] were selected for the 8-week internship phase of the trial. During this phase, trainees saw up to two participants (one via telemedicine and one in-person) to implement the BA treatment. Only trainees who achieved competence, as assessed by standardized role-plays and therapy quality assessments, were selected to deliver BA during the trial.

Supervision
During the training phase, clinical leads provided weekly supervision with NSPs and SPs (separately to avoid contamination) to review and discuss cases and reinforce BA training. All treatment providers recorded all BA sessions for training and supervision purposes and for fidelity measures. Treatment providers who required additional assistance to gain competence completed an additional training case with additional supervision.

During the trial, NSPs have continued weekly supervision meetings with their designated clinical lead. In addition, NSPs engage in monthly measurement-based supervision where clinical leads and NSPs rate individual audio-recorded sessions for therapy quality—the extent to which a psychological treatment was implemented well enough to achieve its expected effects [53]. Audio recordings are rated using the 20-item Q-HAP [51] for BA treatment-specific and common therapeutic (e.g., collaboration, empathy) skills. The individual NSP who conducted the session (self-rating), 2–4 peers (peer ratings), and a clinical lead (expert rating) evaluate a selected session. The summed score by peers for each subscale is used to estimate therapy quality for the session and is compared to the expert ratings. As the trainee NSPs gain experience in delivering BA and rating audio-recorded sessions, the supervision format will evolve from expert led (that is, the clinical lead and specialist who is skilled in the delivery of the psychological

| Table 2 Training outline by provider |
|----------------------------------------|
| **Non Specialist Provider** | **Specialist Provider** |
| **Day 1** | **Introduction to the trial** |
| • Background in perinatal depression and anxiety | • Introduction to the trial |
| • Mood measures (EPDS + GAD-7) | • Mood measures (EPDS + GAD-7) |
| • Foundational skills for therapy: EMPOWERS | • Introduction to the principles of BA |
| • Introduction to the principles of BA | • BA: sessions 1–2 |
| • BA: session 1 | |
| **Day 2** | **BA: sessions 2–3** |
| • BA: sessions 4–8 | • BA: sessions 3–8 |
| • Multiple choice exam | | |
| • Competency role-play | • Safety protocols |
| • Training evaluation | • Multiple choice exam |
| | • Competency role-play |
| | • Training evaluation |
of the investigators have been validated and previously used in one or more health (e.g., [22, 23, 40, 41, 54, 55, 61, 68, 69]. The as-

at 9 – Chicago.

Fig. 2). We anticipate that 50% of participants will be re-

N recruit and retain a sample size of

informed consent to screen 9140 from which we will

participants for potential eligibility and obtaining

Across the three hubs, we anticipate assessing 18,280

Participant recruitment

N required final sample is

produced anxiety (mean GAD-7 = 8.07, SD = 5.50 [23]), the

NSP) and 80% power for our secondary hypothesis of re-

wise comparisons between the four arms (i.e., telemedi-

out, and provide additional power (up to 76%) for pair-

vide greater than 80% power. To account for 20% drop

require 274 participants in each of the four arms to pro-

alpha = 0.025 (i.e., 0.05/2 for our two key comparisons of

EPDS score of 0.79 in relation to the mean), and an

4.68 [54]). Using a non-inferiority margin of 10% (i.e.,

condition is based on an EPDS mean estimate of 7.93 (SD =

Using a non-inferiority margin of 10% (i.e.,

EPDS score of 0.79 in relation to the mean), and an

alpha = 0.025 (i.e., 0.05/2 for our two key comparisons of interest: telemedicine vs. in-person and SP vs. NSP), we

require 274 participants in each of the four arms to pro-

vide greater than 80% power. To account for 20% drop

out, and provide additional power (up to 76%) for pair-

wise comparisons between the four arms (i.e., telemedi-

cine SP, telemedicine NSP, in-person SP, in-person

NSP) and 80% power for our secondary hypothesis of re-

duced anxiety (mean GAD-7 = 8.07, SD = 5.50 [23]), the

required final sample is N = 1368 (342 per arm).

Sample size

The primary outcome measure is an EPDS mean score

at 3 months post-randomization. The sample size calcu-

lation is based on an EPDS mean estimate of 7.93 (SD =

4.68 [54]). Using a non-inferiority margin of 10% (i.e.,

EPDS score of 0.79 in relation to the mean), and an

alpha = 0.025 (i.e., 0.05/2 for our two key comparisons of interest: telemedicine vs. in-person and SP vs. NSP), we

require 274 participants in each of the four arms to pro-

vide greater than 80% power. To account for 20% drop

out, and provide additional power (up to 76%) for pair-

wise comparisons between the four arms (i.e., telemedi-

cine SP, telemedicine NSP, in-person SP, in-person

NSP) and 80% power for our secondary hypothesis of re-

duced anxiety (mean GAD-7 = 8.07, SD = 5.50 [23]), the

required final sample is N = 1368 (342 per arm).

Participant recruitment

Across the three hubs, we anticipate recruiting 18,280

treatment to peer-led group supervision) [51]. SPs do not attend regular supervision, but the clinical lead is available on an ad hoc basis to reflect real-world conditions.

Fidelity assessments

Independent consultants evaluate up to 5% of all audio sessions by both NSPs and SPs to assess treatment adherence and fidelity during the trial phase. Treatment providers not reaching the cut-off for specific items will receive refresher training by the hub clinical leads.

Outcomes and timing of assessments

Table 3 lists all measures and the timing of assessments. In general, there are measures related to the participant (measured at baseline, 3-, 6-, and 12-month post-randomization), the therapy (session-wise scores and end of treatment), and the participant’s child (assessed at 9–15 months post-childbirth). All measures (Table 3) have been validated and previously used in one or more of the investigators’ trials targeting perinatal mental health (e.g., [22, 23, 40, 41, 54, 55, 61, 68, 69]. The assessment period is extended if there is a treatment hiatus due to perinatal life events (e.g., giving birth, obstetrical complications, or contracting COVID-19).

Nested qualitative study

Interviews are being conducted with various subsets of participants (n = 60) including representation from each of the four arms, treatment completers vs. non-completers, and antenatal vs. postnatal enrollment. A maximum variance sample will be used to capture participants across severity levels, perinatal periods, site key sociodemographic factors, and stakeholder groups. An unblinded data coordinator identifies potential participants. In addition, we are interviewing up to 20 significant others (including spouses or partners of participating mothers), all SPs and NSPs, 10 healthcare providers (obstetricians, family physicians, nurses, midwives, psychiatrists and psychologists not participating in the study), and relevant stakeholders such as patient advocates. Each treatment provider will be interviewed three times, once during each phase of their participation in the trial (beginning, middle, and end) to capture relevant aspects of the intervention during implementation. Finally, we will examine the data to determine the presence of specific barriers, facilitators, and modifications made to the content and delivery of the BA treatment in response to COVID-19 (Figs. 3 and 4).

Methods—allocation, data collection, management, and analysis

Randomization

After informed consent, verification of inclusion/exclusion criteria, and completion of baseline measures, participants are stratified by whether they enrolled antenatally or postnatally then randomized within site to one of the four arms (1:1:1:1) via computer-generated randomization through REDCap™. Since the start of COVID-19 containment efforts in all study jurisdictions, in-person arms have been temporarily suspended (see Fig. 2) to decrease the number of non-urgent visits to hospitals and clinics and to decrease the risk of exposure to COVID-19 for both study participants and treatment providers, in line with institutional guidelines. Pending the duration of the COVID-19 outbreak and its impact on the safety of in-person care, the return to a four-arm trial will include weighting of randomization toward in-person sessions to “balance” the number of individuals who are currently being randomized to telemedicine.

Blinding and masking

Baseline assessments are completed as per participant preference either remotely or on site (paused during COVID-19) at time of recruitment via a secure REDCap™ link prior to randomization. Outcome assessments at 3-, 6-, and 12-month post-randomization are also completed via REDCap™. While participants and providers are aware of treatment allocation, research assistants conducting the recruitment, participant qualitative


### Table 3 Outcomes and timing of assessments

| Study variable | Instrument | Outcome (range) |
|----------------|------------|-----------------|

#### Maternal: measured at baseline and 3-, 6-, and 12-month post-randomization

| Maternal characteristics | Trial Baseline Questionnaire [54, 55] | Self-reported age, education level, gender and sexual orientation, marital status, race, immigrant status and ethnicity, clinical history with depression or anxiety (severity, chronicity, number of prior episodes, and age at first episode), occupational status, number of children, pregnancy intention, pregnancy history, delivery, and birth. |
|--------------------------|-------------------------------------|----------------------------------------------------------------------|

#### Depressive symptoms

| Edinburgh Postnatal Depression Scale (EPDS) [44] | Mean continuous score of a 10-item scale (0–30) |

#### Anxiety symptoms

| Generalized Anxiety Disorder Scale (GAD-7) [45] | Mean continuous score of a 7-item scale (0–21) |

#### Response and remission

| Patient Health Questionnaire-9 (PHQ-9) [56] | Response: PHQ < 10 Remission is defined as PHQ < 5 |

#### Perceived support

| Multidimensional Scale of Perceived Social Support [57] | Mean continuous score of a 12-item scale (1–84) |

#### Disability assessment

| World Health Organization Disability Assessment Schedule (WHODAS) [58] | Mean continuous score of a 12-item scale (0–48) |

#### Quality of life assessment

| EQ 5D-5 Level [59] | Mean continuous score of a 5-item scale (1–25) |

#### Trauma symptoms

| Abbreviated PTSD Checklist (PCL-6) [60] | Mean continuous score of a 6-item scale (1–30) |

#### Patient-reported activation

| Premium Abbreviated Activation Scale [41, 61] | Mean continuous score of a 5-item scale (0–4) and general counseling skills (0–4) |

#### Patient satisfaction

| Client Satisfaction Questionnaire-8 (CSQ-8) [62] | Mean continuous score of an 8-item scale (1–32) |

#### Therapeutic alliance

| Working Alliance Inventory-Short Revise (WAI-SR) [63] | Mean continuous score of a 12-item scale (1–60) |

#### Health service utilization

| Health Service Utilization Form | Total score of a 16-item scale (0–32) |

#### Treatment preference

| Delivery of treatment and treatment provider preference | Score of 0 or 1 |

#### COVID-19 exposure

| 1-item question on COVID-19 exposure | Self-reported |

#### Treatment: measured at every session during treatment, unless otherwise indicated

| Frequency of sessions attended | |

#### Dosage

| Treatment log [64] | |

#### Therapy quality

| Quality of Healthy Activity Program (Q-HAP) [51] | |

#### Session depressive/anxiety

| Session-by-session EPDS [44] and GAD-7 [45] scores | |

#### Homework adherence

| Treatment log [64] | |

#### Adverse or serious AEs

| Anytime an adverse event (AE) or serious AE occurs | Any event that represents a serious threat to the safety of the mother or her child |

#### Health service utilization

| Health Service Utilization Form [65] | Total score of a 16-item scale (0–32) |

#### List of medications

| List of medications | Self-reported list of medications |

#### COVID-19 exposure

| 1-item question on COVID-19 exposure | Self-reported |

#### Child: measured at 9 to 15 months post-child birth unless otherwise indicated

| Assess at birth | |

#### Birth weight and length

| Retrieved from hospital chart or self-report | |

#### Breastfeeding

| Whether breastfeeding and if stopped age stopped [55]. | Total number of months (0–12) |

#### Psychosocial stimulation

| Home Observation Measurement Evaluation [66] | Total score of a 45-item checklist |

#### Mental development

| Bayley Mental Development Scales IV [67] | Mean continuous score of cognitive, receptive, and expressive language development |

---

*Assessment period will be extended to account for post-treatment outcomes when there are perinatal-related interruptions to treatment (e.g., giving birth, obstetrical complications, COVID-19)*

*Only at baseline*

*Measured at 3 months post-randomization only*

*Randomly selected for supervision, rated by self, peers, expert supervisor*

*Self-report will be used when hospital charts are outside of the recruiting site*
interviews, and child in-home 9–15 months post-birth assessments will remain unblinded (Fig. 1; Table 3).

Data collection
All data are collected via REDCap™.

Data management

Quantitative data
De-identified data are collected in identical REDCap™ databases kept on secure institutional servers within each of the three participating cities. De-identified data from the USA hubs are extracted from the hubs’ REDCap™ database, encrypted, and transferred to Toronto, where they are uploaded, entered, and stored in REDCap™.

Qualitative data
All study interviews and focus groups are audio-recorded using a digital voice recorder. Audio files are transcribed and identifiers removed during transcription.

Statistical analyses

Primary analysis
The primary analyses will be run as per-protocol and intent-to-treat, with two-sided significance levels of $p < 0.05$. Demographic (ethnicity, age, marital status) and other baseline variables (e.g., severity and chronicity) will
be checked for differences between study groups using descriptive statistics (means, standard deviations, proportions) and the associated statistical tests (t tests, chi-square tests). The primary outcome (EPDS scores at 3 months post-randomization for telemedicine vs. in-person, and SP vs. NSP) will be analyzed using non-inferiority t tests. One t test will be run to compare treatment modality (is telemedicine non-inferior to in-person). Another t test will be run to compare providers (is NSP non-inferior to SP). Non-inferiority will be assessed by seeing whether the 10% non-inferiority margin is contained in the upper bound of the confidence interval around the difference in EPDS scores (e.g., between telemedicine and in-person). A sensitivity analysis will examine potential differences in baseline and outcome depressive and anxiety symptom scores to determine whether participants recruited and received treatment during the COVID-19 outbreak differed significantly from the larger sample. Multiple imputation methods will be used for data missing at random, with the number of imputations reflecting the percentage of missing data (e.g., if 10% of data is missing, then 10 imputations will be conducted) [70] and using SAS’s Proc MI and Proc MIAN ALYZE. Reasons for dropout will be ascertained from clinician records or by interviewing a subset of the participants who dropped out and coded. Drop-out characteristics will be compared to those completing the study. Sensitivity analyses will be carried out should missing data lead to the use of multiple imputation methods. These analyses will compare the results of the models on the imputed data to the ones with the actual missing data included. All analyses will be carried out using SAS Version 9.4 or later (SAS Institute, Cary, NC, USA).

Secondary analyses
In our secondary analysis, we are interested in (i) assessing the trend in EPDS and GAD-7 scores over time (baseline, 3-, 6-, and 12-month post-randomization) between groups (telemedicine vs. in-person, and SP vs. NSP). These analyses will use linear mixed models and include a group by time interaction term as well as adjust for potential covariates of interest. All child outcomes, including child mental development and the provision of psychosocial stimulation by the mother, will be compared between two groups (antenatal vs. postnatal) at 9–15 months post-childbirth using a two-sample two-sided t test. Sensitivity analyses will be carried out excluding those who dropped out after session one to see if the results are comparable to the entire study group.

Moderation analyses
Clinical severity
Tests of moderation will be conducted to determine whether delivery mode (telemedicine vs. in-person) or agent (SP vs. NSP) is moderated by baseline clinical severity. We expect up to 15% of our sample to be severely depressed (EPDS > 20 [71]). A 2-group comparison with 75 per group and an assumed mean EPDS score of 20.0 (SD = 7.0) [80], will provide 80% power, with an alpha of 0.05, to detect a mean change of 2.3 or greater. Our current sample size including those within severity subgroups described above will be adequately powered to detect medium effect size differences of heterogeneity of treatment effects of symptom severity between groups. This indicates that we have adequate power for clinically meaningful tests. The two groups’ (SP vs. NSP) EPDS scores at 3 months will be compared using a two-sided two-sample t test. Change in EPDS score over time (baseline and every 3 months post-randomization) will also be compared using linear mixed models. We will also examine this for anxiety symptoms at 3 months post-randomization.

Perinatal period
This model will also test whether expectant mothers who receive antenatal treatment benefit more in terms of reduced depressive symptoms than mothers who receive postnatal treatment at 12 months post-randomization. A 2-group comparison with 200 per group and an assumed EPDS mean of 7.93 (SD = 4.68) will provide 90% power, with an alpha of 0.05, to detect a mean change of 1.5 points. This allows us to detect a drop corresponding to a small effect size of 0.3 (i.e., a drop to mean 6.43 on the EPDS). The two groups’ (antenatal vs. postnatal) EPDS scores at 3 months will be compared using a two-sided two-sample t test. Change in EPDS scores over time (baseline and every 3 months post-randomization) also will be compared using linear mixed models including the interaction between group and time. We will examine anxiety symptoms at 12 months post randomization in a linear mixed model controlling for relevant covariates including child age.

Child outcomes
We will examine whether the subset of mothers (up to 75% of the sample) who receive antenatal treatment benefit more in terms of improved child outcomes at 9–15 months than mothers who receive postnatal treatment. A 2-group comparison of 238 per group (antenatal vs. postnatal) and an assumed mean on any Bayley IV raw subscale score of 100, SD = 15 to assess child mental development will provide 80% power, with an alpha of 0.05 to detect a mean clinically-significant change of 3.0 units. Raw and standardized Bayley IV scores of the two groups’ children (antenatal vs. postnatal) at 12 months will be compared using a two-sided, two-sample t test.
Qualitative analysis
All qualitative data will be analyzed using NVivo. We use content analysis with data analysis (coding) conducted by multiple independent raters, for whom interrater reliability is calculated using Kappa (κ) scores. Coding is conducted in a step-wise fashion to facilitate iterative revision and finalization of a coding scheme. Specifically, we first independently code and then discuss a minimum of 3 cases per stakeholder group to achieve a kappa (κ) score of 0.75 or higher (defined as substantial to almost perfect agreement). Qualitative data is then quantified and triangulated across stakeholder groups using our previously established methods [20, 72].

Drop out and follow-up strategies
Participants can withdraw consent and end their participation in the study at any time. We expect 20% of participants to be lost to follow-up. This dropout rate is conservative and has been found in many similar trials using NSP and SP delivered psychological treatments for perinatal depression in the USA and Canada [23, 39, 54, 55]. Based on a Cochrane review [73], prior research on study retention (e.g., [74–76]), and our previous experiences [40, 41, 54, 55], it is realistic to expect a 12-month post-randomization follow-up rate of at least 80% when we incorporate numerous retention strategies, such as questionnaire reminders and remunerations for their completion, obtained secondary contact information from participants, and being flexible with participants’ schedules.

Oversight and monitoring

Trial management
Several committees monitor the progress of the trial (Table 4). Trial monitoring comprises collation and reporting of routine trial process indicators and adverse events. The Data and Safety Monitoring Board (DSMB) consists of a psychiatrist with expertise in perinatal depressive or anxiety symptoms, a medical provider with expertise in providing obstetric care for pregnant women, a psychologist with expertise in the design and implementation of pragmatic clinical trials, and a PhD-level statistician. None of these persons are directly involved in the trial. The Trial Management Committee (TMC) presents regular reports to the Advisory Committee and the DSMB.

Stakeholder engagement and dissemination strategies
The SUMMIT research team works closely with a range of stakeholder partners across North America to inform the development, implementation, and dissemination of the SUMMIT trial. Two key goals include ensuring ample and appropriate stakeholder engagement as well as the delivery of diverse and audience-centered dissemination strategies.

To achieve the first goal of stakeholder engagement, three key steps are being implemented: (i) the creation of a diverse and informative Stakeholder Advisory Committee; (ii) identify and address potential barriers to engagement and implementation; and (iii) conduct an ongoing process evaluation to ensure that the treatment content, training materials and study questionnaires are

Table 4 Study management and committees

| Committee                  | Role                                                                 | Members                                                                 | Frequency     |
|----------------------------|----------------------------------------------------------------------|-------------------------------------------------------------------------|---------------|
| Trial Management Committee | To monitor all aspects of the conduct and progress of the trial, ensure that the protocol is adhered to and take appropriate action to safeguard participants and the quality of the trial. | • Principal investigator from each hub*  
• Trial coordinators  
• Project administrator  
• Data coordinator | Weekly*       |
| Investigator and Advisory Committee | To monitor all aspects of the conduct and progress of the trial, including site-specific safety protocols within and across sites | • All investigators  
• Research coordinators from each site  
• Data coordinator | Biweekly to Monthly |
| Stakeholder Advisory Committee | To provide overall supervision of the trial and ensure that it is being conducted in accordance with the protocol and the relevant regulations. The TMC should approve the trial protocol and any protocol amendments and provide advice to the TMC on all aspects of the trial. Decisions about continuation or termination of the trial or substantial amendments to the protocol are finally the responsibility of the TMC. | • Members of the TMC  
• All investigators  
• Trial/content advisors and consultants  
• All stakeholders | Six-monthly |
| Data Safety Monitoring Board (DSMB) | The DSMB will review the accruing trial serious adverse event reports to assess whether there are any safety issues that should be brought to participants’ attention or any reasons for the trial not to continue. It is the only body that makes recommendations to unblind data and makes further recommendations to the TMC. | • Four members (clinical psychologist, obstetrician, perinatal psychologist, a statistician) with expertise in providing obstetric care for pregnant women, a psychologist with expertise in the design and implementation of pragmatic clinical trials, and a PhD-level statistician | Six-monthly |

*Hub refers to locality (Toronto, Chapel Hill, Chicago)  
*Weekly meetings also held within sites
acceptable and feasible from a multi-stakeholder perspective. Our stakeholder partners are listed on our study website (www.thesummittrial.com) and include individuals with lived experience, patient advocates and community partners, telemedicine partners, clinicians from various professions (nurses, midwives, family practitioners, obstetricians, social workers, psychologists, and psychiatrists), representatives from US-based insurance companies, and policy makers.

To achieve the second goal of audience-centered dissemination strategies, we work with our stakeholders to ensure that our dissemination strategies are inclusive and accessible to a wide range of networks. They include local, provincial/state-, national, and international methods of dissemination, involving press releases, presentations to local organizations and digital brochures, policy briefs, list-serves, and attending scientific meetings and publication of academic and non-academic publications.

**Serious adverse events (SAEs)**
SAEs in this trial include disability or permanent harm, hospitalization for psychiatric reasons, life threatening events in the mother, fetus, neonate or infant, fetal or infant death, major congenital anomaly or birth defects, maternal death, or other serious important medical events such as active suicidal or homicidal ideation. Within 72 h of an SAE, the TMC reports the event to the DSMB, including details of the event, severity of any reactions, phase of the study, and procedures for its resolution, and reports to the Institutional Review Board of record.

The DSMB may also recommend termination or modification of the study in the following conditions: if SAEs are significantly clustered in one or more conditions as determined by the DSMB, followed by an unblinded analysis of all sites where we see patients worsening on depressive and anxiety symptoms by two or more standard deviations from the mean or based on the clinical judgment.

**Potential risk and benefits**
Participants may or may not benefit from the study. The United States Preventive Task Force suggested that there is no-to-minimal harm of evidence-based psychological therapies [15]. If discussion of symptoms causes psychological discomfort or participants experience an exacerbation of depressive or anxiety symptoms, study safety protocols offset these risks. A treatment provider may experience distress if they are excluded from study participation for not meeting competency standards. In addition, NSPs may experience stress while participating as providers owing to their limited experience in this new role. These issues can be discussed at supervision.

In addition, NSPs receive education about techniques in self-care as part of the BA training curriculum.

**Access to data**
A data coordinator oversees the intra-study data sharing process, with input from the Trial Management Committee and trial Biostatistician. The trial Biostatistician has access to cleaned data. Hub PIs have direct access to their own, blinded site’s data and may have access to other sites’ data by request. The datasets analyzed during the current study will be available within 1 year of completing the trial from the corresponding author and upon reasonable request.

**Confidentiality**
Data dispersed to relevant team members are always blinded to participant identity and treatment allocation, except for recruitment RAs, RAs who schedule appointments, the data coordinator, and treatment providers who can access relevant identifying information (e.g., session-wise EPDS and GAD-7 scores). All information is kept in password-protected, encrypted files on encrypted computers and secure servers. Unique study IDs are used to identify the participants with key files encrypted and stored on an encrypted computer or a secure server at each site.

**Discussion**
This trial is designed to compare the clinical benefits of who (NSP vs. SP) and how (telemedicine vs. in-person) effective psychological treatment for perinatal depression and anxiety can be delivered. Our non-inferiority design and analytical strategy will determine if NSPs and telemedicine are comparable to the current standard of usual care (SPs and in-person). Our process evaluation will illuminate relevant barriers and facilitators related to training, supervision, intervention content and delivery across a wide range of stakeholders across several time points of this trial.

As the largest psychological treatment trial for perinatal populations to date, SUMMIT’s findings have great potential to improve access to mental healthcare to address the growing burden of perinatal depression and anxiety. Examining these comparisons has the capacity to support a stepped care model in which we optimize the use of available resources. Continuing and adapting our study during COVID-19 (see Table 5) will allow us to produce results that are relevant to the current and future context of delivering psychological treatments with a patient-centered focus and the highest ethical standards. By reconceptualizing the delivery of psychological treatments in clinical practice, we can rethink the delivery of mental healthcare to implement sustainable, equitable, and patient-centered solutions. In sum, this
research holds promise to improve the accessibility and scalability of brief, evidence-based, psychological treatments for perinatal women worldwide.

**Trial status**
Recruitment commenced in January 2020 and is estimated to be completed by April 2023. Recruitment numbers are updated regularly on the study website (www.thesummittrial.com). Modifications to the protocol that impact study conduct, potentially benefit patients or affect their safety require a formal amendment to the protocol. Amendments are agreed upon by the TMC and approved by relevant IRBs prior to implementation. Amendments for safety concerns are also reviewed by the DSMB prior to implementation. The current protocol version (1.0) was approved on December 18, 2020.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s13063-021-05075-1.

**Additional file 1:** Figure S1. The SPIRIT flow diagram: the schedule of enrollment, intervention and assessments.

**Additional file 2:** SPIRIT checklist.

**Abbreviations**
BA: Behavioral activation; DSMB: Data and Safety Monitoring Board; EPDS: Edinburgh Postnatal Depression Scale; GAD-7: Generalized Anxiety Disorder-7; PCL-6: zes Posttraumatic Stress Disorder Scale; REDCap: Research Electronic Data Capture; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; TMC: Trial Management Committee; TRAD: Translational Research and Development; WebEx: Web-based video conferencing software; Zoom: Video conferencing software; DSMB: Data and Safety Monitoring Board.
and receiving revenue from MindfulNoggin.com, receiving royalties from Psychotherapy Chair. SD reports being a co-founder of Mindful Noggin, Inc. depression and pregnancy. JJK is partly supported by a Small Business reports royalties from UpToDate Inc. for authorship of materials related to The study team and all authors report no conflicts of interest. However, SNV
Competing interests being obtained from all participants.

Ethics approval and consent to participate

Funding
This study is funded as a Pragmatic Clinical Study (PCS) by the Patient-Centered Outcomes Research Institute (PCORI), PCS-2018-1C-10621. The funder was not involved in the design of the study and is not involved in the collection, analysis, and interpretation of data, nor in writing the current manuscript.

Availability of data and materials
Individuals interested in SUMMIT study materials may contact the Study PI.

Ethics approval and consent to participate
Ethical approval has been received from institutional review boards (IRBs) for all Toronto sites through Clinical Trials Ontario (18R5), in Chapel Hill through UNC Biomedical IRB (19-1786), and in Chicago through NorthShore University HealthSystem IRB (EH18-129). Informed consent to participate is being obtained from all participants.

Consent for publication
Not applicable.

Competing interests
The study team and all authors report no conflicts of interest. However, SNW reports royalties from UpToDate Inc. for authorship of materials related to depression and pregnancy. JJK is partly supported by a Small Business Innovation Research award from the National Institute of Mental Health (RS, PI). PR receives support from the Sinai Health System, Morgan Firestone Psychotherapy Chair. SD reports being a co-founder of Mindful Noggin, Inc. and receiving revenue from MindfulNoggin.com, receiving royalties from Guilford Press for books on Behavioral Activation and mindfulness. BHM receives financial support from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto. He directly owns stocks of General Electric (less than $5000). Within the past 3 years, he has also received research support from Eli Lilly (medications for a NIH-funded clinical trial) and Pfizer (medications for a NIH-funded clinical trial). He has been an unpaid consultant to Myriad Neuroscience. AMS is a co-investigator for a Janssen Research and Development study, Optimizing Clinical Screening and treatment for perinatal depression. Birth. 2008;178(8):1301–9.

Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Interventions to prevent perinatal depression: US preventive services task force recommendation statement. Jama. 2019;321(6):580–7.

Byatt N, Xiao RS, Dinh KH, Waring ME. Mental health care use in relation to depressive symptoms among pregnant women in the USA. Arch Womens Ment Health. 2016;19(1):187–91.

Dennis CL, Chung-Lee L. Postpartum depression help-seeking barriers and maternal treatment preferences: a qualitative systematic review. Birth. 2006; 33(4):323–31.

Singla DR, Kohrt BA, Murray UK, Anand A, Chopita BF, Patel V. Psychological treatments for the world: lessons from low-and middle-income countries.
Ann Rev Clin Psychol. 2017;13:149–81. https://doi.org/10.1146/annurev-clinpsy-032816-045217. PMID: 28492687; PMCID: PMC5506549.

19. HoeffT, JT; Fortney, JC; Patel, V; Unützer, J. Task-sharing approaches to improve mental health care in rural and other low-resource settings: a systematic review. J Rural Health. 2018;34(1):48–62.

20. Singla D, Lazarus A, Atif N, Sikander S, Bhatia U, Ahmad I, et al. Someone like us: delivering maternal mental health through peers in two South Asian contexts. J Affect Disord. 2014;168:452–8.

21. O'Mahen HA, Grieve H, Jones J, McGinnicy J, Woodward J, Wilkinson E. Women's experiences of factors affecting treatment engagement and adherence in internet delivered Behavioural Activation for Postnatal Depression. Internet Interv. 2015;2(1):84–90.

22. Patel V, Weobong B, Weiss HA, Anand A, Bhat B, Katti B, et al. The Healthy Activity Program (HAP), a lay counsellor-delivered brief psychological treatment for severe depression, in primary care in India: a randomised controlled trial. Lancet. 2017;389(10065):176–85.

23. Dimidjian S, Goodman SH, Sherwood NE, Simon GE, Ludman EJ, Gallop RJ, et al. A pragmatic randomized clinical trial of behavioral activation for depressed pregnant women. J Consult Clin Psychol. 2017;85(1):26.

24. Singla DR, Lawson A, Kohrt BA, Jung JW, Meng Z, Ratjen C, Zahedi N, Dennis CL, Patel V. Implementation and effectiveness of non-specialist delivered interventions for perinatal mental health in high-income countries: a systematic review and meta-analysis. JAMA Psychiatry. 2021. https://doi.org/10.1001/jamapsychiatry.2020.4565. Epub ahead of print. PMID: 3353904.

25. Singla DR, Lemberg-Pelly S, Lawson A, Zahedi N, Thomas-Jacquies T, Dennis CL. Implementing psychological interventions through nontechnical providers and telemedicine in high-income countries: qualitative study from a multisitekeeper perspective. JMR Mental Health. 2020;7(8):e19271.

26. Lee EW, Denison FC, Hoz K, Reynolds RM. Web-based interventions for prevention and treatment of perinatal mood disorders: a systematic review. BMC Pregnancy Childbirth. 2016;16(1):38.

27. Andrews G. Utility of computerised cognitive-behavioural therapy for depression. Br J Psychiatry. 2010;196(4):257–8.

28. Lokkerbol J, Adema D, Cuijpers P, Reynolds CF, Schulz R, Weehuizen R, et al. Improving the cost-effectiveness of a healthcare system for depressive disorders by implementing telemedicine: a health economist modelling study. Am J Geriatr Psychiatry. 2014;22(3):253–62.

29. Andrews G, Cuijpers P, Craske MG, McEvoy P, Titov N. Computer therapy for the anxiety and depressive disorders is effective, acceptable and practical health care: a meta-analysis. PLoS One. 2010;5(10):e13196.

30. Carlbring P, Andersson G, Cuijpers P, Piper H, Hedman-Lagerlolf E. Internet-based vs. face-to-face cognitive behavior therapy for psychiatric and somatic disorders: an updated systematic review and meta-analysis. Cogn Behav Ther. 2018;47(1):1–18.

31. Dimidjian S, Sinnaeve M, Martell CR, Mezzetti A, Muñoz RF, Levinsohn PM. The origins and current status of behavioral activation treatments for depression. Annu Rev Clin Psychol. 2011;7:38–71.

32. Jacobson NS, Martell CR, Dimidjian S. Behavioral activation treatment for depression: returning to contextual roots. Clin Psychol Sci Pract. 2001;8(3):255–70.

33. Cuijpers P, Van Straten A, Wiersma D, Korten A, Arts W, Hofstee F, et al. Task-sharing approaches to improve engagement in the Mental Health Care Programme for depression, anxiety and activation. Med Care. 2010;48(9):823–36.

34. Spitzer RL, Kroenke K, Williams JB, Group PHQPCS. Validation and utility of a brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092–7.

35. McDermott MM, Newman AB. Preserving clinical trial integrity during the coronavirus pandemic. JAMA. 2020;323(2):1235–6.

36. Chowdhary N, Anand A, Dimidjian S, Shinde S, Weobong B, Balaji M, et al. The Healthy Activity Program lay counsellor delivered treatment for severe depression in India: systematic development and randomised evaluation. Br J Psychiatry. 2016;208(4):381–8.

37. Singla DR, Weobong B, Nadkarni A, Chowdhary N, Shinde S, Anand A, et al. Improving the scalability of psychological treatments in developing countries: an evaluation of peer-led therapy quality assessment in Goa, India. Behav Res Ther. 2014;6053–9.

38. Restivo JL, Mitchell L, Joshi U, Anand A, Gugiu PC, Singla DR, et al. Assessing health worker competence to deliver a brief psychological treatment for depression: development and validation of a scalable measure. J Behav Ther Psychol. 2020;63:253–66.

39. Zimet GD, Hirozumi NL, Zimet SG, Farley GK. The multidimensional scale of perceived social support. J Pers Assess. 1988;52(1):30–41.

40. Üstün TB, Chatterji S, Kostanjsek N, Rehm J, Kennedy C, Epping-Jordan J, et al. Developing the World Health Organization disability assessment schedule 2.0. Bull World Health Organ. 2010;88:115–23.
59. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727–36.

60. Lang AJ, Stein MB. An abbreviated PTSD checklist for use as a screening instrument in primary care. Behav Res Ther. 2005;43(5):585–94.

61. Singla DR, Mackinnon DP, Fuhr DC, Sikander S, Rahman A, Patel V. Multiple mediation analysis of the peer-delivered Thinking Healthy Programme for perinatal depression: findings from two parallel, randomised controlled trials. Br J Psychiatry. 2019. p. 1–8. https://doi.org/10.1192/bjp.2019.184. Epub ahead of print. PMID: 31362799.

62. Attkisson CC, Zwick R. The Client Satisfaction Questionnaire: psychometric properties and correlations with service utilization and psychotherapy outcome. Eval Program Plann. 1982;5(3):233–7.

63. Munder T, Willmers F, Leonhart R, Linster HW, Barth J. Working Alliance Inventory-Short Revised (WAI-SR): psychometric properties in outpatients and inpatients. Clin Psychol Psychother. 2010;17(3):231–9.

64. Fuhr DC, Calvert C, Ronsmans C, Chandra PS, Sikander S, De Silva MJ, et al. Contribution of suicide and injuries to pregnancy-related mortality in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Psychiatry. 2014;1(3):213–25.

65. Brown G. Health service utilization and cost of care questionnaire. Health and Social Service Utilization Research Unit. Hamilton, ON: McMaster University; 2001.

66. Bradley RH, Caldwell BM. The HOME Inventory and family demographics. Dev Psychol. 1984;20(2):315.

67. Bayley N. Bayley scales of infant development and toddler development: technical manual; the PsychCorp; 2006.

68. Aboud FE, Singla DR. Challenges to changing health behaviours in developing countries: a critical overview. Soc Sci Med. 2012;73(4):589–94.

69. Singla DR, Hollon SD, Velleman R, Weobong B, Nadkarni A, Fairburn CG, Bhat B, Gurtav M, Anand A, McCambridge J, Dimidjian S, Patel V. Temporal pathways of change in two randomized controlled trials for depression and harmful drinking in Goa, India. Psychol Med. 2020;50(1):68–76. https://doi.org/10.1017/S0033291719003963. Epub 2019 Jan 8. PMID: 30616698; PMCID: PMC6945222.

70. Bodner TE. What improves with increased missing data imputations? Struct Equ Model Multidiscip J. 2008;15(4):651–75.

71. McCabe-Beane JE, Segre LS, Perkhounkova Y, Stuart S, O’Hara MW. The identification of severity ranges for the Edinburgh Postnatal Depression Scale. J Reprod Infant Psychol. 2016;34(3):293–303.

72. Singla DR, Kumbakumba E. The development and implementation of a theory-informed, integrated mother-child intervention in rural Uganda. Soc Sci Med. 2015;147:242–51.

73. Edwards P, Roberts J, Clarke M, DiGuiseppi C, Pratap S, Wentz R, et al. Increasing response rates to postal questionnaires: systematic review. Bmj. 2002;324(7347):1183.

74. Seed M, Juarez M, Alnator R. Improving recruitment and retention rates in preventative longitudinal research with adolescent mothers. J Child Adolescent Psychiatric Nurs. 2009;22(3):150–3.

75. Katz KS, El-Mohandes A, Johnson DM, Jarrett M, Rose A, Cober M. Retention of low income mothers in a parenting intervention study. J Community Health. 2001;26(3):203–18.

76. Hough RL, Takle H, Renker V, Shields P, Glatstein J. Recruitment and retention of homeless mentally ill participants in research. J Consult Clin Psychol. 1996;64(5):881–91.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.